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Native interactions of the major molecular chaperones
Hsp70 and Hsp90 with known client proteins typically involve
several attendant co-chaperone proteins. Among the activities
attributed to partner co-chaperones are regulation of chaperone ATPase activity or nucleotide exchange (1, 2), recruitment
of additional chaperones and co-chaperones (3), targeting of the
client complex for degradation (4), or subcellular localization
(5). A commonly studied chaperone/client system is the assembly pathway for steroid receptor complexes in which multiple
chaperones and co-chaperones participate in a multistep, dynamic assembly process (6, 7). The co-chaperone Hop, which
can bind both Hsp70 and Hsp90, plays a key role in recruiting
Hsp90 to preexisting receptor-Hsp70 complexes (3, 8, 9), thus
promoting assembly progression and ultimate functional maturation of the receptor.
Similar to many Hsp70 and Hsp90 co-chaperones, tetratri-
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copeptide repeat (TPR)1 domains of Hop mediate binding to
Hsp (10, 11). Whereas the Hsp-binding co-chaperones most
often contain a single TPR domain, Hop contains three distinct
TPR domains. The C-terminal region of cytoplasmic forms of
Hsp70 and Hsp90, both of which terminate with the amino acid
sequence EEVD, have been implicated as the binding sites for
Hop and for some other TPR co-chaperones (12–14); however,
some TPR co-chaperones clearly interact with other Hsp regions (15, 16). Since Hop contains multiple TPR domains, the
opportunity exists for Hop to simultaneously bind the EEVD
sites of both Hsp70 and Hsp90.
In a major advance toward understanding how TPR domains
interface with the Hsp EEVD region, co-crystal structures were
obtained for either of two Hop TPR domains complexed with an
EEVD-containing peptide (14). One co-crystal contained the
N-terminal TPR domain of Hop, TPR1, and the octapeptide
GPTIEEVD that corresponds to the Hsp70 C terminus. The
other co-crystal contained one of the central TPR domains,
TPR2a, in complex with the pentapeptide MEEVD that corresponds to the C-terminal sequence of Hsp90. Similar to some
other reported TPR domains, both of the Hop TPR domains
consisted of an antiparallel ␣-helical stack that forms a large
groove along one surface of the domain. The EEVD-containing
peptides lodged within this groove but in distinct orientations
that related to TPR side-chain differences within the groove
and unique amino acids in either peptide. In both co-crystal
structures, basic TPR side chains within the groove formed salt
bridges with acidic peptide side chains, forming what was
termed the carboxylate clamp. Consistent with the TPR2a cocrystal structure, point mutation of a conserved carboxylate
clamp position in any of several Hsp90-binding TPR co-chaperones has been shown to disrupt Hsp90 binding (13).
The co-crystal results suggest a straightforward model for an
Hsp70-Hop-Hsp90 complex in which the C terminus of Hsp70
binds TPR1 of Hop and the C terminus of Hsp90 binds TPR2a
of Hop. However, experimental results suggest that additional
Hop domains influence Hsp binding. For instance, mutations
within the C-terminal DP-domain of Hop greatly inhibit Hsp70
binding (3, 17), and deletions within TPR2b, the third TPR
domain of Hop, can reduce Hsp90 binding (18). Furthermore,
as shown below, truncation of the EEVD from Hsp70 had little
effect on Hop binding. To help resolve relevant interactions
between full-length proteins, we have taken advantage of crystallographic structures and recent insight from sequence comparisons between Hop regions to design novel Hop point mutants that were assessed for Hsp binding, support of steroid
receptor function in vivo, and conformational changes.

1
The abbreviations used are: TPR, tetratricopeptide repeat; GST,
glutathione S-transferase; RL, reticulocyte lysate; DOC, deoxycorticosterone; PR, progesterone receptor; GR, glucocorticoid receptor.
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The Hop/Sti1 co-chaperone binds to both Hsp70 and
Hsp90. Biochemical and co-crystallographic studies
have suggested that the EEVD-containing C terminus of
Hsp70 or Hsp90 binds specifically to one of the Hop
tetratricopeptide repeat domains, TPR1 or TPR2a, respectively. Mutational analyses of Hsp70 and Hop were
undertaken to better characterize interactions between
the C terminus of Hsp70 and Hop domains. Surprisingly,
truncation of EEVD plus as many as 34 additional amino
acids from the Hsp70 C terminus did not reduce the
ability of Hsp70 mutants to co-immunoprecipitate with
Hop, although further truncation eliminated Hop binding. Hop point mutations targeting a carboxylate clamp
position in TPR1 disrupted Hsp70 binding, as was expected; however, similar point mutations in TPR2a or
TPR2b also inhibited Hsp70 binding in some settings.
Using a yeast-based in vivo assay for Hop function, wild
type Hop and TPR2b mutants could fully complement
deletion of Sti1p; TPR1 and TPR2a point mutants could
partially restore activity. Conformations of Hop and
Hop mutants were probed by limited proteolysis. The
TPR1 mutant digested in a similar manner to wild type;
however, TPR2a and TPR2b mutants each displayed
greater resistance to chymotryptic digestion. All point
mutants retained an ability to dimerize, and none appeared to be grossly misfolded. These results raise questions about current models for Hop/Hsp70 interaction.
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EXPERIMENTAL PROCEDURES

expression plasmid p425GPD, which contains a LEU2 nutritional
marker, a 2 origin of replication, and a constitutive GPD transcriptional promoter.
Yeast Assays for Hormone-induced Reporter Gene Expression—Hormone induction assays were conducted as previously described (20).
Briefly, yeast strains were grown in selective media at 25 °C to an A600
of 0.05– 0.12 units. Growth was monitored by spectrophotometry for 30
min before hormone addition to ensure that the culture was in exponential phase. Deoxycorticosterone (DOC) was added to the culture at
50 nM final concentration. To assay for ␤-galactosidase activity, 100 l
of culture was withdrawn and immediately added to 100 l of the
Gal-Screen™ substrate (Tropix, Bedford, MA) in 96-well microtiter
plates at room temperature. Samples were taken at 10-min intervals
until 70 – 80 min after hormone addition. The plate was read in a
luminometer 2 h after the last sample was collected.
To determine the rate of reporter expression, ␤-galactosidase induction curves were first generated by plotting relative light units against
the A600 of the culture sample. Regression analysis of the linear portion
of each data set yielded a best fit line (typically R2 ⬎ 0.98) whose slope
is the growth-normalized rate of ␤-galactosidase expression.
Yeast Cell Extracts and Western Immunoblots—To prepare whole cell
extracts, washed cell pellets were resuspended in cracking buffer (8 M
urea, 5% (w/v) SDS, 40 mM Tris-HCl, pH 7.5, 0.1 mM EDTA, 0.04% (w/v)
bromphenol blue) at 4 ml/g of cells. Cells were homogenized with glass
beads in a Mini Bead Beater (Biospec Products, Bartlesville, OK). Cell
homogenates were centrifuged to remove insoluble material and heated
at 95 °C for 5 min. Lysate aliquots (10 –15 l) were separated by
SDS-PAGE, transferred to polyvinylidene difluoride membrane, and
immunostained for Sti1p (mouse monoclonal IgG ST-2), Hop (mouse
monoclonal IgG F5), or the yeast ribosomal protein L3 (mouse monoclonal IgG anti-L3).
Recombinant Protein Expression and Purification—BL21 bacterial
cells were transformed with each of the various expression plasmids for
protein expression. Briefly, 1 liter of LB medium plus 100 g/ml ampicillin was inoculated 1:100 with an overnight culture of transformed
bacteria. Cells were grown at 37 °C until the A600 reached 0.5, at which
time 100 mM isopropyl ␤-D-galactopyranoside was added to a final
concentration of 0.4 mM. Cells were incubated for an additional 3 h at
room temperature. Bacterial cell pellets were resuspended in 10 ml of
buffer A (20 mM Tris, pH 7.5, 1 mM EDTA, and 5 mM dithiothreitol plus
Complete Mini protease inhibitor mixture (Roche Applied Science)) and
sonicated to generate cell extracts.
His-tagged proteins were purified by metal affinity chromatography
according to manufacturer’s instructions (Qiaexpressionist Kit, Qiagen,
Valencia, CA). Extracts were applied to Ni2⫹-nitrilotriacetic acid affinity resin and incubated for 1 h at 4 °C. Resins were washed three times
in 1 ml wash buffer (50 mM NaH2PO4, pH 8.0, 300 mM NaCl, and 20 mM
imidazole). Protein was eluted at 250 mM imidazole.
GST-tagged bacterial extracts were rocked batch-wise with glutathione-Sepharose 4B resin (Amersham Biosciences) for 1 h at 4 °C. Proteins were eluted from the glutathione resin with 50 mM Tris-HCl
containing 10 mM reduced glutathione.
Untagged Hop forms were purified by three-step chromatography
(Akta FPLC, Amersham Biosciences). First, bacterial extracts containing untagged proteins were loaded on a HiPrep16/10 Heparin-Sepharose column equilibrated in buffer A, and proteins were eluted with a
salt gradient of 0 – 0.5 M KCl in buffer A. Peak fractions containing Hop
were identified by gel electrophoresis and pooled. For the next purification step, samples were loaded on a Resource Q column and eluted
with 0 –500 mM KCl. Peak fractions were again pooled and then applied
to a 16/60 Superdex 200 column equilibrated with 20 mM Tris, pH 7.5,
250 mM KCl, and 5 mM MgCl2. Final peak fractions for Hop were pooled
and concentrated using Amicon Centricon-10 filters (Millipore Corp.,
Billerica, MA). The purity of all Hop forms was judged to be greater
than 95%.
GST-Hop Pull-down Assays—Previously purified and quantitated
GST-tagged Hop forms were incubated batch-wise with glutathioneSepharose 4B (5 g of protein plus 20 l of bed volume resin) for 30 min
at room temperature on a rocking platform and washed three times in
1 ml of incubation buffer (20 mM Tris, pH 7.5, 100 mM KCl, 5 mM MgCl2,
and 2 mM dithiothreitol). Resin pellets were resuspended in 150 l of
incubation buffer plus 10 g of purified Hsp70 for 30 min at 30 °C.
Resin was subsequently washed three times in 1 ml of ice-cold incubation buffer containing 0.01% Nonidet P-40. Bound proteins were eluted
with SDS sample buffer, separated on gels, and visualized by Coomassie Blue staining.
Protease Digestion of Recombinant Hop Forms—Purified His-tagged
Hop forms were subjected to partial proteolytic analysis (21) using
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cDNA Mutagenesis and Construction of Expression Plasmids—A series of Hsp70 C-terminal truncation mutants was generated by introducing stop codons into the rat Hsc70 cDNA. Mutant cDNAs were
generated by site-directed mutagenesis (QuikChangeTM kit, Stratagene, La Jolla, CA) using the in vitro expression plasmid rat Hsc70/
pSPUTK as template. The following mutants were generated, named
according to the final amino acid encoded: N642, N614, N608, N604,
N595, N575, N534, and N425.
Hop point mutations were generated in a similar manner using
human Hop/pSPUTK as template. Mutations in the following domains
were generated: TPR1, Y27A, K73E, and K73A; TPR2a, K301E, K301A,
R305E, and R305A; TPR2b, K429E, K429A, R433E, and R433A; DP1,
D140A and D149A; AP1, D140A/D149A. A mutant in the DP2 domain
(AP2) was constructed previously (3). Sequences for mutagenic primers
are available on request. All mutant cDNA sequences were verified by
automated sequencing.
For bacterial expression of recombinant proteins, mutant and wild
type cDNA were cloned into pET28 for expression of untagged proteins
in bacteria, pET30 for expression of His-tagged proteins, and pGEX5X-3 for expression of GST-tagged proteins. When mutagenesis or PCR
products were employed for subcloning, all insert sequences were verified by automated sequencing.
In Vitro Binding Assays—Radiolabeled Hsp70 or Hop forms were
generated by in vitro expression (TNT Kit; Promega, Madison, WI) in
the presence of [35S]methionine. A 5-l aliquot of each synthesis reaction was separated by SDS-PAGE and visualized by autoradiography;
the labeled products were quantitated by densitometry (Fluor-S MultiImager; Bio-Rad). Molar equivalents of each radiolabeled product were
added to rabbit reticulocyte lysate (1:1 lysate, Green Hectares, Oregon,
WI) for immunoprecipitation and receptor assembly trials. Mouse
monoclonal antibodies specific for Hop (F5), Hsp70 (BB70), or Hsp90
(H90-10) were preadsorbed to protein G-Sepharose (1 g of antibody/l
of packed resin). For each immunoprecipitation reaction, 100 l of
reticulocyte lysate (RL) supplemented with a radiolabeled product were
added to a 10-l immunoresin pellet. The mixtures were incubated for
30 min at 30 °C with brief vortexing every 5 min. Resin-bound complexes were washed four times in 1 ml of wash buffer (20 mM Tris-HCl,
pH 7.4, 50 mM NaCl, 0.5% (v/v) Tween 20), resuspended in 20 l of 2⫻
SDS-PAGE sample buffer, and separated by SDS-PAGE. Gels were
Coomassie-stained to visualize total proteins and then dried and autoradiographed to visualize bound radiolabeled proteins.
Comparisons of wild type and mutated Hop forms assembling with
PR complexes were performed as described previously (3). Briefly, recombinant chicken PR was immunopurified from Sf9 insect cell extracts
using monoclonal antibody PR22 preadsorbed to protein A-Sepharose.
Each assembly reaction contained 10 l of PR resin (representing 1 g
of PR) and an equimolar amount of a radiolabeled Hop form in 200 l of
RL (supplemented with an ATP-regenerating system to promote assembly reactions and 20 g/ml geldanamycin to favor recovery of intermediate PR complexes containing Hop). Samples were incubated 30 min at
30 °C with brief vortexing at 5-min intervals to resuspend resin. Resinbound complexes were washed three times in 1 ml of wash buffer, and
bound proteins were separated by SDS-PAGE. Gels were stained with
Coomassie Blue followed by autoradiography of dried gels. Bands on
x-ray film were quantitated by densitometry.
Yeast Strains and Plasmids—All Saccharomyces cerevisiae strains
were generated in the W303a background (MATa leu2-112 ura3-1
trp1-1 his3-11,15 ade2-1 can1-100 GAL SUC2). Plasmids were introduced into yeast using the lithium acetate/polyethylene gycol protocol.
Two to four independent transformants of each construction were analyzed. Strains were propagated in selective media consisting of 0.67%
(w/v) yeast nitrogen base without amino acids, 2% (w/v) glucose, the
appropriate synthetic complete supplement mixture (Q-biogene, Carlsbad, CA), and 1.6% (w/v) agar for plates.
To generate the Sti1-minus yeast strain (sti1⌬0), the entire coding
region of STI1 was replaced with the Schizosaccharomyces pombe HIS5
gene flanked by loxP sites; the His marker was subsequently removed
by transformation with a plasmid encoding the Cre recombinase (19).
Gene deletion was confirmed by yeast colony PCR, and the absence of
Sti1p was confirmed by Western blot analysis with the anti-Sti1 monoclonal antibody ST2 (provided by D. Toft).
As described previously (20), the glucocorticoid receptor (GR) expression strain contained a pG/N795 plasmid constitutively expressing rat
GR and the GRE-lacZ reporter plasmid pUC⌬SS-26X. Wild type or
mutant Hop cDNA was introduced into a yeast expression vector by
ligating a HindIII/EcoRV fragment from pSPUTK into the constitutive
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FIG. 1. Hop TPR domains. A, known domains for Hsp90, Hop, and
Hsp70 are illustrated. Structural information is available for some
domains (solid borders) but not for others (dashed borders). The EEVDcontaining C-terminal sequences of Hsp90 and Hsp70 are indicated.
The lines indicate domain/domain interactions thought to occur between TPR2a of Hop and the C terminus of Hsp90 or TPR1 of Hop and
the C terminus of Hsp70. B, the co-crystal structure for Hop TPR2a plus
an MEEVD peptide is depicted in two orientations. In each view, the
positively charged carboxylate clamp side chains for Lys301 and Arg305
are illustrated with space-filling cages, and negatively charged side
chains in the MEEVD peptide are indicated.
chymotrypsin (Type VIII; Sigma) or subtilisin Carlsberg (Type VIII;
Sigma). Digestion mixtures containing 30 g of Hop and 300 ng of
protease in 50 mM Tris-HCl, pH 8.0 (60-l total volume) were incubated
at 30 °C over a 60-min time course with the removal of 10-l aliquots at
1, 5, 15, and 60 min. Proteolysis was quenched by the addition of 10 mM
phenylmethylsulfonyl fluoride and/or by placing the sample in an acetone/dry ice bath. Protein fragments were separated on precast 4 –20%
gradient gel (Bio-Rad) and Coomassie-stained to visualize protease
digestion patterns. Bands were quantitated by densitometry.
RESULTS

Known structural/functional domains of Hsp90, Hsp70, and
Hop are illustrated in Fig. 1A. Hsp90 contains an N-terminal
ATPase domain (22), a large middle domain (23), and a Cterminal region of unknown conformation that contains a
strong dimerization site. There is evidence for peptide binding
by both the ATPase and middle domains of Hsp90 (24). Hsp70

contains an N-terminal ATPase domain (25) unrelated to the
corresponding Hsp90 domain, a central peptide binding domain (26), and a C-terminal 10-kDa domain (27). Hop contains
three TPR domains plus a C-terminal DP domain and a putative central DP domain (further described below). As indicated,
TPR1 is thought to bind the C-terminal PTIEEVD sequence of
Hsp70, whereas Hop TPR2a is thought to bind the C-terminal
MEEVD sequence of Hsp90 (14).
In Fig. 1B, the TPR2a/MEEVD co-crystal structure is depicted in two alternate views. The TPR motifs in antiparallel
␣-helices form the peptide binding groove. Positively charged
side chains of Arg305 and Lys301 that form the TPR2a carboxylate clamp are highlighted, as are the negatively charged side
chains of the MEEVD peptide. The TPR1/GPTIEEVD co-crystal shows a similar overall structure, although the carboxylate
clamp residues and peptide side chains are oriented in a unique
manner.
Hsp70 C-terminal Sequences Necessary for Hop Binding—To
test directly which C-terminal sequences of Hsp70 are required
for Hop binding, a series of C-terminal truncation mutants was
prepared (Fig. 2A), and each mutant was compared with fulllength Hsp70 in a Hop co-immunoprecipitation assay (Fig. 2B).
The smallest truncation (N642) lacks the terminal EEVD site,
the next truncation (N614) lacks sequences through the GGMPrepeat region (dashed underlined region), and additional mutants progressively remove upstream highly conserved sequence
patches (solid underlined regions). Equivalent amounts of radiolabeled Hsp70 forms were added to rabbit reticulocyte lysate, and
the Hsp90-Hop-Hsp70 complex was immunoprecipitated using
an anti-Hop antibody. Proteins were separated by SDS gel electrophoresis and visualized by Coomassie staining (Fig. 2B, top
panel) or autoradiography (middle panel). The amounts of radiolabeled Hsp70 added to each mixture are shown in an additional
autoradiograph (bottom panel).
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FIG. 2. Interaction of Hsp70 C-terminal truncation mutants
with Hop. A, shown is the amino acid sequence for the C-terminal
region (positions 587– 646) of rat Hsc70 (PIR accession number
P08109). The highlighted sequences are regions of highest conservation
among Hsp70 forms (solid underline), the GGMP repeat motif that is
found in some Hsp70 family members (dashed underline), and the
octapeptide (boldface letters) used for co-crystallization with Hop TPR1.
Stop codons were introduced in this region to generate a series of
truncation mutants, as indicated. B, wild-type (WT) and mutant cDNA
were used to generate radiolabeled protein products. Molar equivalents
of each Hsp70 form (Input) were added to normal rabbit reticulocyte
lysate, from which Hop complexes were immunoprecipitated. Immune
complexes were separated by SDS gel electrophoresis and visualized by
Coomassie staining for total proteins (top panel) or by autoradiography
to detect bound radiolabeled Hsp70 forms (middle panel). Stained
bands, which represent rabbit Hsp90 and Hsp70 that co-precipitate
with Hop and the anti-Hop heavy chain (HC), are indicated on the left.
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FIG. 3. Sequence similarity between the N-terminal and C-terminal
regions of Hop. In the alignment of
amino acids 6 –187 with 362–539 of human Hop (PIR accession number
A38093), regions of similarity are observed between TPR1 and TPR2b (shaded
box); the carboxylate clamp positions targeted for mutagenesis are indicated (boldface type and underlined). The latter portion of each sequence contains a DP
repeat motif (open box); the various DP
elements are indicated (boldface type), as
are residues targeted for mutagenesis
(underlined). Alignments were generated
using the Gap component of SeqWeb (version 2.1; Accelrys).

charge would not impact overall domain folding while maximizing inhibition of interactions with a negatively charged
substrate. Second, alanine substitution was used to neutralize
the basic charge while minimizing the likelihood for unintended conformational changes. Both carboxylate clamp positions were separately mutated for TPR2a (Lys301 or Arg305) and
TPR2b (Lys429 or Arg433). A single carboxylate clamp position
was mutated in TPR1 (Lys73), and we used a previously reported (31) TPR1 point mutant that disrupts Hsp70 binding
(Y27A). For the DP2 domain, we used the previously reported
AP2 construct (3) in which Asp of both DP repeats was substituted with Ala. For DP1, we generated single alanine mutants
(D140A and D149A) plus the combined double mutant (AP1).
Wild type and mutant cDNAs were expressed in vitro to
generate radiolabeled products. Molar equivalents of each radiolabeled form were added to RL and tested for co-immunoprecipitation with Hsp90 or Hsp70 or tested for assembly with
progesterone receptor (PR) complexes (Fig. 4). For the TPR
carboxylate clamp mutants, data are only shown for the glutamic acid substitutions; however, the alternative alanine substitutions gave essentially identical results (not shown).
Looking first at Hsp90-binding properties of the mutants
(Fig. 4, upper set of panels), only mutations in TPR2a were
defective for binding Hsp90. This finding is consistent with
earlier reports that have linked TPR2a with Hsp90 binding.
Normal Hsp90 binding was observed with TPR2b point mutants, which contrasts somewhat with an earlier report that
deletions within TPR2b inhibit Hsp90 binding (18). However,
weakened binding by the earlier deletion constructs may be
attributable to unintended alterations in Hop conformation
that impacted TPR2a activity.
Multiple domain mutants affected Hsp70 binding (Fig. 4,
middle set of panels). First, TPR1 mutants lost binding, an
observation consistent with earlier indications that this domain plays a key role in Hsp70 binding. The DP2 mutant
(AP2), as seen before, also had greatly reduced binding to
Hsp70. Unexpectedly, however, we observed that both TPR2a
and TPR2b mutants failed to bind Hsp70, indicating for the
first time that these domains somehow influence Hsp70 interactions. DP1 mutants were the only domain mutants that
retained normal binding to Hsp70.
The ability of Hop mutants to assemble with PR complexes
(Fig. 4, lower set of panels) mostly corresponded with deficiencies in Hsp90 or Hsp70 binding. Exceptions are TPR2b mutants that fail to bind Hsp70 yet appear to assemble normally
with the PR complex. Note that TPR1 mutants retain a partial
ability to assemble with PR complexes despite our observation
that these mutants bind poorly to Hsp70. Therefore, it is still
possible for Hop mutants that are defective in Hsp70 binding to
assemble with receptor complexes, presumably reflecting inter-
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Contrary to expectations, truncation of the C-terminal
EEVD (N642) or more extensive truncations (N614 and N608)
had little effect on recovery of Hsp70 in Hop complexes. Only
when the final 40 –50 amino acids were truncated (N604 and
N595) was there a major loss of Hop binding. An additional
truncation mutant that terminates at position 575 also failed to
bind Hsp70 (not shown), thus minimizing the likelihood that
N604 and N595 artifactually block Hop access to upstream
binding sites. On the other hand, in probing the region from
590 to 606 that contains sequences necessary for Hop binding,
several single and double point mutations were generated, but
none of these inhibited Hop binding (not shown). Point mutant
results argue against the presence of a discrete Hop binding
site in this region. Although this limited mutational analysis
does not identify sequences in the C-terminal region of Hsp70
that are sufficient for Hop binding, we can conclude that the
EEVD and adjacent GGMP repeat region are not required for
Hop binding in our assay.
Mutagenic Analysis of Hop Domains—To further explore
Hop/Hsp70 interactions, we generated domain-specific point
mutants of Hop to verify that TPR1 is required and to test
whether other Hop domains participate in Hsp70 binding.
Careful sequence analysis of Hop revealed a previously overlooked symmetry between the N-terminal and C-terminal regions of Hop. Fig. 3 shows an alignment of TPR1 plus downstream sequences compared with TPR2b and downstream
sequences. We have previously shown that sequences downstream from TPR2b contain a DP-repeat motif (underlined
sites) that contributes to an independent structural domain
(17). Truncation or point mutations within the so-called DP
domain lessens binding of Hop to Hsp70 without affecting Hop
binding to Hsp90. As the alignment in Fig. 3 reveals, there is
similarity between the C-terminal DP domain and sequences
correspondingly positioned downstream from TPR1. We refer
to this recently recognized N-terminal DP region as DP1 and
the original DP domain as DP2.
Point mutants were generated for each of the three TPR
domains as well as the two DP regions. Within the TPR domains, point mutations targeted basic residues in the carboxylate clamp. For TPR2b, whose structure has not been solved,
basic amino acids corresponding to the carboxylate clamp positions in TPR1 were mutated (double underlines in Fig. 3). In
other Hsp90-binding TPR proteins, point mutations of basic
amino acids that form the carboxylate clamp have been shown
to efficiently disrupt Hsp90 binding (13, 28 –30). In the present
study, two alternative rationales were used for point mutagenesis of carboxylate clamp positions. First, either Lys or Arg was
converted to glutamic acid, thus reversing the charge at this
position. Since the charged side chain projects into the solvent
space of the binding groove, we reasoned that reversing the
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actions with receptor-associated Hsp90. Finally, in this particular data set, the DP1 mutant D140A appears to assemble less
well with PR, but this apparent defect was not reproducible in
replicate experiments.
Due to the unexpected finding that point mutants of TPR2a
and TPR2b, as well as the TPR1 mutants, failed to co-precipitate with Hsp70 complexes from RL, these mutants were directly tested for Hsp70 binding by a GST pull-down approach
(Fig. 5). A series of GST fusion proteins was prepared in which
glutathione S-transferase was fused to the N terminus of wild
type Hop or Hop mutants. Either GST alone or one of the
GST-Hop constructs was purified on glutathione beads and
incubated with purified Hsp70. In a typical experiment (Fig.
5A), Hsp70 associated weakly with GST alone, reflecting the
level of nonspecific Hsp70 binding. Specific binding of Hsp70 to
each Hop form was estimated from densitometric analysis of
gel bands from four separate experiments after subtracting the
level of nonspecific Hsp70 (GST alone) from each sample. As
seen in a summary of these data (Fig. 5B), Hsp70 bound R305E
(TPR2a mutant) equally as well as wild type Hop, in contrast
with reduced co-immunoprecipitation from RL (Fig. 4). However, consistent with the RL co-precipitation results, K73E
(TPR1) and K429E (TPR2b) were both defective for binding
Hsp70. Therefore, it consistently appears that TPR2b along
with TPR1 is somehow involved in Hsp70 binding. TPR2a, on
the other hand, impacts Hsp70 binding in a context-dependent
manner that is evident only in the more complex RL
environment.

FIG. 5. Direct interactions between purified Hsp70 and Hop
forms. A, purified GST fusion proteins (5 g) or a molar equivalent of
GST alone was immobilized on glutathione resin (20 l pellet) and
incubated with purified Hsp70 (20 g) for 30 min at 30 °C (total volume
150 l). After washing, bound proteins were eluted from resin with SDS
sample buffer, separated on gels, and visualized by Coomassie staining.
The region of the stained gel containing Hsp70 and the GST-Hop fusion
(⬃80 kDa) is shown. A corresponding image of the smaller GST alone
band is inserted in the first lane. B, gel bands from four replicate
experiments were quantitated by scanning densitometry. The OD value
of Hsp70 bound nonspecifically to GST alone was subtracted from other
Hsp70 OD values to obtain specific binding levels. The average and S.D.
values for Hsp70 recovered in each sample are plotted.

Cellular Activity of Hop Mutants—A physiological role for
Hop in steroid receptor signaling was first demonstrated in a
yeast model, where Lindquist and co-workers (32) showed that
deletion of the gene for STI1, the close S. cerevisiae ortholog of
vertebrate Hop, impaired the transcriptional activity of glucocorticoid receptor. Sti1p and human Hop share ⬃50% amino
acid sequence similarity, and we have shown that Sti1p can
functionally substitute for Hop in a cell-free assay for steroid
receptor assembly (3). To test the functional ability of Hop
mutants in vivo, we first established that human Hop could
functionally replace Sti1p in a yeast model for steroid receptor
function. Wild type or a strain lacking the STI1 gene (sti1⌬0)
was transformed with a plasmid that constitutively expresses
rat GR and a lacZ reporter plasmid under control of glucocorticoid-responsive elements. Additionally, sti1⌬0 cells were
transformed with an empty vector or a plasmid constitutively
expressing human Hop. Hormone-induced ␤-galactosidase activity was measured in cells treated or not with 50 nM DOC, a
preferred GR agonist in the yeast model. As shown in Fig. 6A,
DOC stimulated a 15-fold increase in enzymatic activity in wild
type cells. Deletion of STI1 abrogated hormone-induced reporter activity, but stimulation was fully restored in sti1⌬0
cells expressing human Hop. The ability of Hop mutants to
rescue the sti1⌬0 phenotype was tested in similar assays (Fig.
6B). Mutants in TPR1 (K73E) and TPR2a (R305E) could partially restore GR activity but only to ⬃50% the level of wild
type Hop. No significant loss of activity was observed with the
TPR2b mutant (K429E), and the DP-1 double mutant (AP1)
consistently displays somewhat enhanced activity when compared with wild type Hop. The only mutant with a complete
lack of activity is the DP2 mutant (AP2).
Since reduced function in this assay could be due to differences in protein expression levels rather than inherent differences in activity, yeast culture extracts were assayed for relative Hop protein levels by Western immunoblotting (Fig. 6C).
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FIG. 4. Interaction of Hop point mutants with Hsp90, Hsp70,
and progesterone receptor. Radiolabeled wild type and mutant
forms of Hop were synthesized in vitro. A molar equivalent of each form
(Input; autoradiograph in uppermost panel) was added to aliquots of
reticulocyte lysate prior to immunoprecipitations of Hsp90 (top panel
pair) or Hsp70 (middle panel pair) or assembly of PR complexes (bottom
panel pair). The upper panel of each pair is a Coomassie-stained gel to
visualize total proteins, and the lower panel is the corresponding autoradiograph that shows the level of each radiolabeled Hop form recovered in respective complexes.
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K73E and R305E were present at levels equal to or greater
than that of wild type Hop, so the reduced activity of these
mutants cannot be attributed to limiting protein. K429E and
AP1 mutants also accumulated at wild type levels; thus, the
elevated activity of AP1 is not due to overexpression in yeast.
AP2 accumulates to about half the level of wild type Hop, but

DISCUSSION

These studies were intended to experimentally address the
nature of interactions between Hsp70 and the co-chaperone
Hop. Previous findings have suggested that the TPR1 domain
of Hop binds to C-terminal sequences in Hsp70 (35, 36), and a
co-crystal structure for TPR1 complexed with an octapeptide
that corresponds to the EEVD-containing C terminus of Hsp70
further supported this view (14). However, several observations in the present study suggest that Hop/Hsp70 interactions
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FIG. 6. Activity of Hop mutants in vivo. Human Hop and mutants
were tested for the ability to rescue defects in glucocorticoid signaling in
yeast strains lacking Sti1p, the yeast ortholog for Hop. A, hormoneinducible ␤-galactosidase activity was measured in GR reporter strains
in either a wild type background (STI1) or in yeasts with a disrupted
gene (sti1⌬0) that were transformed either with a control vector or a
vector expressing human Hop. Cell cultures were treated with or without 50 nM DOC, and reporter expression was quantitated as described
under “Experimental Procedures.” The values shown are averages and
S.E. for three replicate cultures. B, GR reporter cells in the sti1⌬0
background were transformed with empty vector or vector expressing
the Hop form indicated. Reporter expression rates were measured after
DOC treatment. C, levels of Hop protein in each strain were estimated
by Western immunostaining yeast extracts with anti-Hop antibody F5;
as a loading control, samples were also immunostained for ribosomal
protein L3.

this modest difference is unlikely to account for the complete
loss of activity in the AP2 strain.
Conformational Analysis of Hop Mutants—We have previously reported that AP2 and other mutations in the DP2 region
display heightened sensitivity to proteolytic digestion and altered partial proteolytic patterns. As shown in Fig. 7, Hop
domain mutants were analyzed by partial proteolysis for indications that mutant conformation differs from wild type Hop.
Purified recombinant proteins were digested with chymotrypsin, which cleaves at positions with large hydrophobic side
chains or with subtilisin Carlsberg, which cleaves more nonspecifically. Trypsin, which cleaves at basic amino acids, was
not employed, since mutation of basic amino acids in the TPR
mutants would confound interpretation of digestion patterns.
For subtilisin and chymotryptic digests, 2– 4 replicate digestions were analyzed for pattern reproducibility, and, in the case
of TPR mutants, both glutamic acid and alanine substitutions
were tested. The fragment patterns obtained were consistent
between replicates and between the alternative TPR mutants.
In comparing chymotryptic digestion patterns (Fig. 7A),
there were only a few qualitative differences in band patterns
that we consistently observed. The most notable difference is
the resistance of certain mutant forms to initial cleavage. This
is perhaps best illustrated by comparing half-lives of fulllength proteins (Fig. 7B). Bands corresponding to full-length
protein were quantitated by densitometry, and values were
plotted versus duration of digestion. From these data, the halflife (i.e. time at which one-half the original amount of fulllength protein remains) was calculated for each Hop form.
Full-length wild type was degraded with a half-life of ⬃40 s. In
contrast, the TPR2a and TPR2b mutants (R305E and K429E,
respectively) had half-lives of 100 –120 s, indicating that these
mutants are more resistant to chymotryptic cleavage. The
TPR1 and DP mutants varied less from wild type.
Hop forms were similarly subjected to limited digestion with
subtilisin, but, in contrast to chymotryptic digests, full-length
wild type and mutant proteins were cleaved at similar rates. As
an example, the rates of subtilisin digestion for wild type and
R305E were identical as were the major fragment patterns
(Fig. 7C), although differences in less abundant fragments
were observed. The subtilisin results suggest that overall conformations between mutants are similar, whereas the chymotryptic results suggest a change in the TPR2a and TPR2b mutant conformations such that enzyme access is restricted at one
or more particularly sensitive cleavage sites.
Hop is reported to exist in a dimeric state (33, 34), although
the structural basis and functional significance of dimerization
is unknown. To test whether TPR or DP1 mutants might affect
the Hop dimeric state, purified proteins were analyzed by gel
filtration (Fig. 8). All forms eluted with similar retention volumes corresponding to the anticipated dimeric size of ⬃120
kDa. None of the forms displayed a tendency toward aggregation, yet a minor fraction of each sample migrated as a small
peak that corresponds in predicted size to a tetrameric complex. The similarity of profiles among all Hop forms suggests
that a dimeric state is retained and that gross misfolding is not
occurring with any mutant.
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FIG. 8. Oligomeric state of Hop and Hop point mutants. Recombinant forms of wild type Hop (WT) and Hop point mutants were
purified by FPLC and analyzed by gel filtration through Sephacryl
S-200 media (⬃100 g of each protein). A standard curve was generated
for the column using molecular weight standards (upper left panel), and
the approximate retention volume and size for all Hop forms is indicated on the curve (dashed line). Other panels show individual filtration
profiles for each Hop form (A280 versus retention volume).

are more complex and involve additional sequences in both Hop
and Hsp70.
The Hop Binding Site in Hsp70 —Contrary to expectations
from earlier studies, truncation of the Hsp70 EEVD sequence
plus as many as 34 upstream amino acids (N608) failed to
significantly reduce the ability of mutant Hsp70 forms to bind
Hop (Fig. 2). However, since extending the truncation through

position 605 (N604) or beyond resulted in a dramatic reduction
in Hop binding, some sequences in the C-terminal region of
Hsp70 are clearly necessary for Hop binding. Crystal structures for a peptide corresponding to amino acids 542– 646 of the
rat Hsc70 C terminus have recently been solved (27). The
portion resolved in the crystal structures spanned amino acids
542 to ⬃610. Four slightly variant structures were observed,
but each revealed a helix-loop-helix structure in which amino
acids 542–553 formed one helix and 564 – 610 formed the much
longer helix. It is perhaps noteworthy that we observed loss of
Hop binding as we began truncating sequences (residues 608 –
604) corresponding to the end of this long helix. Unfortunately,
the GPTIEEVD (residues 639 – 646) and GGMP-repeat (residues 615– 635) portions of the crystallized peptide were not
resolved in x-ray diffractions, suggesting at least that these
motifs do not form a stable interaction with other C-terminal
sequences.
In an attempt to refine localization of minimal C-terminal
sequences necessary for Hop binding, we generated N-terminal
truncations of Hsp70 that lacked the well defined ATPase and
peptide binding domains, but none of these constructs displayed significant binding to Hop (not shown). The ADP-bound
state of Hsp70 is required for efficient binding to Hop (37, 38).
Therefore, the ATPase domain of Hsp70 somehow communicates with C-terminal sequences to which Hop binds. Although
we can conclude that the GGMP-EEVD region is not strictly
required for Hop binding, we nonetheless suspect, as discussed
below, that direct interactions between the Hsp70 EEVD tail
and the Hop TPR1 domain are physiologically relevant.
What Roles do Hop Domains Play in Hsp70 Binding?—Consistent with predictions from current models, point mutation of
carboxylate clamp residues in TPR1 disrupts Hsp70 binding
(Figs. 4 and 5) and Hop function (Fig. 6), so the TPR1 domain
plays a critical role. There have been clear indications, however, that other regions of Hop can have a profound influence
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FIG. 7. Conformational analysis of Hop mutants by limited proteolysis. A, purified His-tagged Hop forms were digested with chymotrypsin for the times indicated. Resulting samples were separated by SDS gel electrophoresis, and fragment patterns were visualized by Coomassie
staining. B, to obtain an estimate for the chymotryptic stability of each Hop form, stained bands representing full-length Hop remaining at each
digestion time point were quantitated by densitometry. The time at which protein was reduced to one-half the starting level is plotted (n ⫽ 3). C,
wild type Hop and the TPR2a point mutant R305E were digested with subtilisin over a 60-min time course.
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During the progressive assembly of steroid receptor complexes,
Hop plays an important, transient role, but little is known
about the molecular mechanisms that direct receptor transit
from intermediate to mature complexes. ATP hydrolysis and
changes in the nucleotide-bound states of Hsp70 and Hsp90 are
important, probably because these lead to changes in Hsp
conformation and co-chaperone interactions. Hop, whose binding to either Hsp is nucleotide-sensitive and can affect ATPase
activities (37–39), is in position to stimulate and coordinate
Hsp structural changes and help translate these into remodeling of receptor complexes.
In order to reconcile our present studies of Hop/Hsp70 interactions with previous reports and to place these findings in the
context of receptor maturation, the following speculative model
is proffered. We propose that a region of Hsp70 upstream from
the EEVD terminus binds TPR1 and that this non-EEVD interaction is critical for initial Hsp70 binding to Hop. Subsequently, within the context of the receptor heterocomplex and
ATP hydrolysis, the EEVD tail displaces the upstream Hsp70
site from TPR1. This putative rearrangement of Hop/Hsp70
interactions would in turn stimulate a change in Hsp70 or
Hsp90 behavior that promotes re-engineering of the receptor
heterocomplex. In this conceptual model, EEVD/TPR1 interaction serves as a secondary regulatory signal rather than a
primary binding interface.
Freeman et al. (40) published evidence that the EEVD tail
can interact with other regions of Hsp70, so there may be
intramolecular interactions of EEVD that change with Hsp70
status such that the EEVD tail becomes available for TPR1
binding in a regulated manner. Structural data on the peptide
binding and C-terminal domains of Hsp70 have also suggested
domain/domain interactions (27). Recall also that Hop binding
is sensitive to the nucleotide-bound state of Hsp70. Therefore,
the ATPase domain of Hsp70 communicates with C-terminal
sequences of Hsp70 to which Hop binds. In addition to Hop’s
adaptor role in bringing together Hsp70 and Hsp90 in a common complex, we think our results add a novel structural
dimension to a model (38) in which Hop also monitors change in
Hsp70 status and stimulates additional change that bears on
the chaperone machinery and modeling of steroid receptor
complexes.
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